An ex vivo study found cannabigerol (CBG) relaxes human pulmonary arteries through endothelium-dependent mechanisms involving nitric oxide, cyclooxygenase, and potassium channels, modified by hypertension and high cholesterol.
Cardiovascular researchers and pulmonary hypertension specialists.
CBG vasorelaxation required intact endothelium
What the researchers found
CBG relaxed human pulmonary arteries through endothelium-dependent mechanisms involving cyclooxygenase, nitric oxide, K+ channels, and likely CB1/CB2, PPARgamma, GPR55, and TRPV1 receptors. Hypertension and hypercholesterolaemia modified the response.
Why it matters
First study showing CBG can relax human pulmonary arteries, with specific mechanisms identified and clinical comorbidity effects documented.
The numbers in context
At least 4 mechanistic pathways; response modified by hypertension and hypercholesterolaemia; endothelium removal abolished the effect.
How the study worked
Ex vivo study using human pulmonary artery segments. Vascular reactivity measured with selective pathway inhibitors. Post-hoc comorbidity analysis.
What this study cannot tell us
Ex vivo tissue. Post-hoc comorbidity analysis. CBG concentrations may not be achievable orally. Surgical patients may not represent general population.
How to read the evidence
First human tissue demonstration with pathway analysis, but ex vivo design limits translation.
When this study was published
2025 study providing first CBG data in human pulmonary vasculature.
The bigger picture
CBG combined with anti-inflammatory and antioxidant properties could be relevant for cardiovascular applications, though mild potency tempers expectations.
Questions still open
- Could CBG benefit pulmonary hypertension patients?
- How does CBG compare to CBD in pulmonary arteries?
Common questions
What is CBG?
Could CBG help with pulmonary hypertension?
Read the original research
Ex vivo study of the vasorelaxant activity induced by cannabigerol in human pulmonary artery- the role of endothelium, sex and selected clinical factors.
Biochemical pharmacology, 242(Pt 1), 117383
Citation
Krzyżewska, Anna; Kloza, Monika; Kozłowski, Mirosław; Galicka, Anna; Kozłowska, Hanna. (2025). Ex vivo study of the vasorelaxant activity induced by cannabigerol in human pulmonary artery- the role of endothelium, sex and selected clinical factors.. Biochemical pharmacology, 242(Pt 1), 117383. https://doi.org/10.1016/j.bcp.2025.117383
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk